MASH cirrhosis treatment, fibrosis reversal, and population screening were cited by experts as hepatology's biggest gaps.
Meena Bansal, MD
Advertisement
Meena Bansal, MD, is a professor of medicine of liver diseases, the system chief of the Division of Liver Diseases, and the director of the MASLD/MASH Center of Excellence at the Icahn School of Medicine at Mount Sinai.
Articles by Meena Bansal, MD
Resmetirom boosts MASH cardiovascular protection, lowering LDL cholesterol and Lp(a) even on statins, and pushes routine Lp(a) testing.
Meena Bansal, MD, discusses the evolving MASH pipeline and why precision phenotyping, biomarkers, and cardiovascular outcomes data remain critical gaps.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Walcker Named President of Cardinal’s The Specialty Alliance, With Strengths in GI, Urology
2
5 Questions Dermatology Patients May Have About Newly-Approved Bemotrizinol
3
Venetoclax-Obinutuzumab Tops Acalabrutinib in First-Line CLL
4
Ontada Analysis Finds GLP-1 RA Use Linked to Improved Survival in Patients With Cancer
5